Shionogi to divest Japanese pharma manufacturing operation
This article was originally published in Scrip
Shionogi has reached an agreement to sell a domestic wholly owned pharmaceutical contract manufacturing subsidiary to a Japanese private equity fund, as part of an ongoing effort to focus on its core business of developing and marketing prescription drugs.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.